Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Enanta Pharmaceuticals, Inc. before investing.

In this article, we go over a few key elements for understanding Enanta Pharmaceuticals, Inc.’s stock price such as:

• Enanta Pharmaceuticals, Inc.’s current stock price and volume
• Why Enanta Pharmaceuticals, Inc.’s stock price changed recently
• Upgrades and downgrades for ENTA from analysts
• ENTA’s stock price momentum as measured by its relative strength

About Enanta Pharmaceuticals, Inc. (ENTA)

Before we jump into Enanta Pharmaceuticals, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company’s product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Want to learn more about Enanta Pharmaceuticals, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Enanta Pharmaceuticals, Inc..

Enanta Pharmaceuticals, Inc.’s Stock Price as of Market Close

As of November 26, 2025, 4:00 PM, CST, Enanta Pharmaceuticals, Inc.’s stock price was $13.940.

Enanta Pharmaceuticals, Inc. is up 2.05% from its previous closing price of $13.660.

During the last market session, Enanta Pharmaceuticals, Inc.’s stock traded between $13.500 and $14.210. Currently, there are approximately 21.38 million shares outstanding for Enanta Pharmaceuticals, Inc..

Enanta Pharmaceuticals, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Enanta Pharmaceuticals, Inc. Stock Price History

Enanta Pharmaceuticals, Inc.’s (ENTA) price is currently up 27.19% so far this month.

During the month of November, Enanta Pharmaceuticals, Inc.’s stock price has reached a high of $14.210 and a low of $10.220.

Over the last year, Enanta Pharmaceuticals, Inc. has hit prices as high as $15.340 and as low as $4.090. Year to date, Enanta Pharmaceuticals, Inc.’s stock is up 142.43%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Enanta Pharmaceuticals, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of November 25, 2025,, no analysts have changed their rating of Enanta Pharmaceuticals, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Enanta Pharmaceuticals, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Enanta Pharmaceuticals, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Enanta Pharmaceuticals, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Enanta Pharmaceuticals, Inc. (ENTA) by visiting AAII Stock Evaluator.

Relative Price Strength of Enanta Pharmaceuticals, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of November 25, 2025, Enanta Pharmaceuticals, Inc. has a weighted four-quarter relative price strength of 18.73%, which translates to a Momentum Score of 90 and is considered to be Very Strong.

Want to learn more about how Enanta Pharmaceuticals, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Enanta Pharmaceuticals, Inc. Stock Price: Bottom Line

As of November 26, 2025, Enanta Pharmaceuticals, Inc.’s stock price is $13.940, which is up 2.05% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Enanta Pharmaceuticals, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.